Prospective Study of the Prosigna Assay on Neoadjuvant Clinical Decision-making in Women With HR+/Her2- Breast Cancer
Clinical trial NCT03749421 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT03749421
- Sponsor
- Dana-Farber Cancer Institute
- Status
- ACTIVE_NOT_RECRUITING
- Study type
- OBSERVATIONAL
- Start date
- 2019-03-21
- Primary completion
- 2023-11-29
- Enrollment
- 60
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.